#weight-loss Tech News.
2 stories in the last 7 days
The latest weight-loss news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks weight-loss across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Pfizer's experimental weight-loss drug berobenatide requires only a monthly injection, unlike weekly shots from Novo Nordisk and Eli Lilly. Phase 2b trials showed comparable results. The market could reach $150 billion annually by 2035. Pfizer's drug offers convenience and scalability advantages.
The United Kingdom approved Novo Nordisk's weight-loss pill, marking the company's first entry into the European market with an oral obesity treatment. The regulatory decision allows Novo to compete with injectable rivals using a daily tablet formulation.
Summaries by ByteBrief